{"DataElement":{"publicId":"14540962","version":"1","preferredName":"Adverse Events Supplemental Qualifiers Dataset Immune Effector Cell Associated Neurotoxicity Syndrome Assessment ICANS Grade","preferredDefinition":"The assessment grading of severity of Immune Effector Cell Associated Neurotoxicity (ICANS) as per immune-effector cell-associated encephalopathy (ICE) tool.","longName":"SUPPAE_QVAL_AEICANSRES","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"14540958","version":"1","preferredName":"Adverse Events Supplemental Qualifiers Dataset Immune Effector Cell Associated Neurotoxicity Syndrome Assessment","preferredDefinition":"A dataset containing supplemental information, specifically non-standard variables, to parent records in the adverse events domain.:Neurotoxicity associated with immune effector cell therapy. It may be characterized by aphasia, altered level of consciousness, motor weakness, seizures, and cerebral edema._The final result of a determination of the value, significance, or extent of.","longName":"6819753v1.00:14540960v1.00","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"6819753","version":"1","preferredName":"Adverse Events Supplemental Qualifiers Dataset","preferredDefinition":"A dataset containing supplemental information, specifically non-standard variables, to parent records in the adverse events domain.","longName":"C147185","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adverse Events Supplemental Qualifiers Dataset","conceptCode":"C147185","definition":"A dataset containing supplemental information, specifically non-standard variables, to parent records in the adverse events domain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DFF23F4-C1A1-5F5B-E053-F662850A7D89","latestVersionIndicator":"Yes","beginDate":"2019-07-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-18","modifiedBy":"ONEDATA","dateModified":"2019-07-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"14540960","version":"1","preferredName":"Immune Effector Cell Associated Neurotoxicity Syndrome Assessment","preferredDefinition":"Neurotoxicity associated with immune effector cell therapy. It may be characterized by aphasia, altered level of consciousness, motor weakness, seizures, and cerebral edema._The final result of a determination of the value, significance, or extent of.","longName":"C162909:C25217","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune Effector Cell Associated Neurotoxicity Syndrome","conceptCode":"C162909","definition":"Neurotoxicity associated with immune effector cell therapy. It may be characterized by aphasia, altered level of consciousness, motor weakness, seizures, and cerebral edema.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0801F776-F560-166C-E063-731AD00A1E31","latestVersionIndicator":"Yes","beginDate":"2023-10-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-10-18","modifiedBy":"MMADDINENI","dateModified":"2023-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0801E330-03D5-101F-E063-731AD00AE4F8","latestVersionIndicator":"Yes","beginDate":"2023-10-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-10-18","modifiedBy":"MMADDINENI","dateModified":"2024-01-11","changeDescription":null,"administrativeNotes":"10/18/2023: Created DEC(CADSR0002962)-MM","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"11105666","version":"1.1","preferredName":"ICANS Grade","preferredDefinition":"A position on a scale of intensity or amount or quality.","longName":"11105666v1.10","context":"AMC","contextVersion":"1","type":"Enumerated","dataType":"ALPHANUMERIC","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Grade 1","valueDescription":null,"ValueMeaning":{"publicId":"11105673","version":"1","preferredName":"Immune Effector Cell Associated Neurotoxicity Syndrome Grade 1","longName":"11105673v1.00","preferredDefinition":"Immune effector cell-associated neurotoxicity syndrome (ICANS) characterized by an immune-effector cell-associated encephalopathy (ICE) tool score of 7, 8, or 9, and the ability of the affected individual to awaken spontaneously.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune Effector Cell Associated Neurotoxicity Syndrome Grade 1","conceptCode":"C188936","definition":"Immune effector cell-associated neurotoxicity syndrome (ICANS) characterized by an immune-effector cell-associated encephalopathy (ICE) tool score of 7, 8, or 9 (for adults and children over 12), or a Cornell Assessment of Pediatric Delirium (CAPD) score of less than 9 (for children 12 and under), and the ability of the affected individual to awaken spontaneously.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E61773D4-8E81-68ED-E053-731AD00A9B4A","latestVersionIndicator":"Yes","beginDate":"2022-08-12","endDate":null,"createdBy":"TSESU","dateCreated":"2022-08-12","modifiedBy":"TSESU","dateModified":"2023-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0811871D-49F5-3B5D-E063-731AD00AAFE9","beginDate":"2022-08-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-10-27","modifiedBy":"KUMMEROA","dateModified":"2023-10-27","deletedIndicator":"No"},{"value":"Grade 2","valueDescription":null,"ValueMeaning":{"publicId":"11105674","version":"1","preferredName":"Immune Effector Cell Associated Neurotoxicity Syndrome Grade 2","longName":"11105674v1.00","preferredDefinition":"Immune effector cell-associated neurotoxicity syndrome (ICANS) characterized by an immune-effector cell-associated encephalopathy (ICE) tool score of 3, 4, 5, or 6, and the ability of the affected individual to awaken to voice commands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune Effector Cell Associated Neurotoxicity Syndrome Grade 2","conceptCode":"C188937","definition":"Immune effector cell-associated neurotoxicity syndrome (ICANS) characterized by an immune-effector cell-associated encephalopathy (ICE) tool score of 3, 4, 5, or 6 (for adults and children over 12), or a Cornell Assessment of Pediatric Delirium (CAPD) score of less than 9 (for children 12 and under), and the ability of the affected individual to awaken to voice commands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E61773D4-8E82-68ED-E053-731AD00A9B4A","latestVersionIndicator":"Yes","beginDate":"2022-08-12","endDate":null,"createdBy":"TSESU","dateCreated":"2022-08-12","modifiedBy":"TSESU","dateModified":"2023-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0811871D-49F6-3B5D-E063-731AD00AAFE9","beginDate":"2022-08-12","endDate":null,"createdBy":"TSESU","dateCreated":"2023-10-19","modifiedBy":"TSESU","dateModified":"2023-10-19","deletedIndicator":"No"},{"value":"Grade 3","valueDescription":null,"ValueMeaning":{"publicId":"14542569","version":"1","preferredName":"Immune Effector Cell Associated Neurotoxicity Syndrome Grade 3","longName":"14542569v1.00","preferredDefinition":"Immune effector cell-associated neurotoxicity syndrome (ICANS) characterized by an immune-effector cell-associated encephalopathy (ICE) tool score of 0, 1, or 2, the ability of the affected individual to awaken only to tactile stimulus, clinical focal or generalized seizures that resolve rapidly, or non-convulsive seizures detected by electroencephalography (EEG) that resolve with intervention, and local cerebral edema evident on neuroimaging.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune Effector Cell Associated Neurotoxicity Syndrome Grade 3","conceptCode":"C188939","definition":"Immune effector cell-associated neurotoxicity syndrome (ICANS) characterized by an immune-effector cell-associated encephalopathy (ICE) tool score of 0, 1, or 2 (for adults and children over 12), or a Cornell Assessment of Pediatric Delirium (CAPD) score of greater than or equal to 9 (for children 12 and under), the ability of the affected individual to awaken only to tactile stimulus, clinical focal or generalized seizures that resolve rapidly, or non-convulsive seizures detected by electroencephalography (EEG) that resolve with intervention, and local cerebral edema evident on neuroimaging.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08119078-DDCC-3CB6-E063-731AD00AD614","latestVersionIndicator":"Yes","beginDate":"2023-10-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-10-19","modifiedBy":"KUMMEROA","dateModified":"2023-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"08119078-DDCE-3CB6-E063-731AD00AD614","beginDate":"2023-10-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-10-19","modifiedBy":"KUMMEROA","dateModified":"2023-10-19","deletedIndicator":"No"},{"value":"Grade 4","valueDescription":null,"ValueMeaning":{"publicId":"14542570","version":"1","preferredName":"Immune Effector Cell Associated Neurotoxicity Syndrome Grade 4","longName":"14542570v1.00","preferredDefinition":"Immune effector cell-associated neurotoxicity syndrome (ICANS) characterized by an immune-effector cell-associated encephalopathy (ICE) tool score of 0, the inability of the affected individual to be arousable without vigorous or repetitive tactile stimuli, life-threatening prolonged (greater than 5 minutes) seizures, or repetitive clinical or electroencephalographically-detected seizures without ever returning to baseline, deep focal motor weakness, diffuse cerebral edema evident on neuroimaging, decerebrate or decorticate posturing, cranial nerve VI palsy, papilledema or Cushing's triad (bradycardia, hypertension, respiratory depression).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune Effector Cell Associated Neurotoxicity Syndrome Grade 4","conceptCode":"C188940","definition":"Immune effector cell-associated neurotoxicity syndrome (ICANS) characterized by an immune-effector cell-associated encephalopathy (ICE) tool score of 0 or if the ICE scale cannot be performed (for adults and children over 12), or if the Cornell Assessment of Pediatric Delirium (CAPD) scale cannot be performed (for children 12 and under), the inability of the affected individual to be arousable without vigorous or repetitive tactile stimuli, life-threatening prolonged (greater than 5 minutes) seizures, or repetitive clinical or electroencephalographically-detected seizures without ever returning to baseline, deep focal motor weakness, diffuse cerebral edema evident on neuroimaging, decerebrate or decorticate posturing, cranial nerve VI palsy, papilledema or Cushing's triad (bradycardia, hypertension, respiratory depression).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08119078-DDCD-3CB6-E063-731AD00AD614","latestVersionIndicator":"Yes","beginDate":"2023-10-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-10-19","modifiedBy":"KUMMEROA","dateModified":"2023-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"08119078-DDCF-3CB6-E063-731AD00AD614","beginDate":"2023-10-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-10-19","modifiedBy":"KUMMEROA","dateModified":"2023-10-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2453188","version":"1","preferredName":"Grade","preferredDefinition":"A position on a scale of intensity or amount or quality.","longName":"C48309","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade","conceptCode":"C48309","definition":"A position on a scale of intensity or amount or quality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"0DDD1E7C-BBFA-66D1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-28","modifiedBy":"ONEDATA","dateModified":"2006-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08118724-24A7-3B59-E063-731AD00A3AE7","latestVersionIndicator":"Yes","beginDate":"2022-08-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-10-19","modifiedBy":"KUMMEROA","dateModified":"2023-10-27","changeDescription":null,"administrativeNotes":"2023.10.19 Created to remove and replace 2 PVs and remove part of def where no concept used. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What is the Immune Effector Cell Associated Neurotoxicity (ICANS) grade?","url":null,"context":"COG"},{"name":"COG TEXT 1","type":"Alternate Question Text","description":"What is the ICANS assessment score?","url":null,"context":"COG"},{"name":"COG TEXT 2","type":"Alternate Question Text","description":"ICANS assessment score","url":null,"context":"COG"},{"name":"COG TEXT 3","type":"Alternate Question Text","description":"ICANS grade","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08020B83-4376-22C1-E063-731AD00AC543","latestVersionIndicator":"Yes","beginDate":"2023-10-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-10-18","modifiedBy":"MMADDINENI","dateModified":"2024-01-11","changeDescription":null,"administrativeNotes":"10/18/2023: Created CDE(CADSR0002962)-MM","unresolvedIssues":null,"deletedIndicator":"No"}}